April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Evaluation of the α5β1-integrin-inhibitor CLT-28643 in a trabeculectomy rabbit model
Author Affiliations & Notes
  • Maximilian Schultheiss
    Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Sven Schnichels
    Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Eva-Maria Konrad
    Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Karl-Ulrich Bartz-Schmidt
    Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Grit Zahn
    Clanotech AB Stockholm, Stockholm, Sweden
  • Patrizia Caldirola
    Clanotech AB Stockholm, Stockholm, Sweden
  • Mario G Fsadni
    Clanotech AB Stockholm, Stockholm, Sweden
    International Pharm-Med Ltd, Hertfordshire, United Kingdom
  • Ninus Caram-Lelham
    Clanotech AB Stockholm, Stockholm, Sweden
    Encecor, Uppsala, Sweden
  • Martin Stephan Spitzer
    Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany
  • Footnotes
    Commercial Relationships Maximilian Schultheiss, Clanotech AB (F); Sven Schnichels, Clanotech AB (F); Eva-Maria Konrad, None; Karl-Ulrich Bartz-Schmidt, Clanotech AB (F); Grit Zahn, Clanotech AB (E); Patrizia Caldirola, Clanotech AB (E); Mario Fsadni, Clanotech AB (E), International Pharm-Med Ltd (E); Ninus Caram-Lelham, Clanotech AB (E), Encecor (E); Martin Spitzer, Clanotech AB (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3206. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maximilian Schultheiss, Sven Schnichels, Eva-Maria Konrad, Karl-Ulrich Bartz-Schmidt, Grit Zahn, Patrizia Caldirola, Mario G Fsadni, Ninus Caram-Lelham, Martin Stephan Spitzer; Evaluation of the α5β1-integrin-inhibitor CLT-28643 in a trabeculectomy rabbit model. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3206. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Bleb failure after glaucoma filtering surgery (GFS) is mainly caused by wound healing and scarring with myofibroblasts playing a crucial role in this process. There is still a high medical need for better tolerated therapeutics than the currently used Mitomycin-C (MMC). α5β1-integrin plays a pivotal role in angiogenesis, inflammation and the activation of residing fibroblasts to myofibroblasts. CLT-28643 is an integrin-inhibitor targeting α5β1-integrin, and can be expected to inhibit scarring after GFS thereby enhancing bleb survival. This is the first study investigating the effect of CLT-28643 in GFS.

Methods: We conducted a double-blinded trabeculectomy-study with 24 rabbits. The right eyes were divided in three groups: 8 eyes received intraoperative MMC (sponge application, 0.04%, for 2 minutes) and placebo eye drops postoperatively (A); 8 eye received subconjunctival CLT-28643 intraoperatively and placebo eye drops postoperatively (B); and in 8 eyes CLT-28643 was applied intraoperatively and as eye drops postoperatively 4 times a day (C). Trabeculectomy was performed on the left eyes of 12 rabbits without any adjunctive treatment (D) and 12 left eye were not operated (E). Clinical assessment included IOP-measurement by Schiötz tonometry, slit lamp examination (bleb survival and Würzburg bleb score) and photographs of the blebs. Four weeks after trabeculectomy the rabbits were sacrificed and processed for histology.

Results: CLT-28643 treatment (group B and C) compared to group D resulted in a significantly prolonged bleb survival and a better bleb score. IOP was significantly lowered in all trabeculectomy groups. IOP and bleb survival were comparable for CLT28643 and MMC treated groups and superior to vehicle treated control eyes. Clinically and histologically CLT-28643 was non-toxic and very well tolerated.

Conclusions: The data of this pilot study suggest that the integrin-inhibitor CLT-28643 may improve the outcome of trabeculectomy.

Keywords: 765 wound healing • 519 extracellular matrix • 503 drug toxicity/drug effects  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×